Anastrozole Suppliers & Bulk Manufacturers
Available Forms: Oral Tablet
Available Strengths: 1 mg
Reference Brands: Arimidex®(US & EU)
Category:
Oncology Cancer Care
Anastrozole 1 mg Tablets are used in oncology to treat hormone receptor-positive breast cancer in postmenopausal women. Available as Arimidex® and generic versions, Anastrozole works by inhibiting estrogen production, slowing the growth of estrogen-dependent tumors. Approved in both the U.S. and EU, it is commonly used for early-stage and metastatic breast cancer treatment.
Anastrozole is available in Oral Tablet
and strengths such as 1 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Anastrozole is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Anastrozole can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Anastrozole 1 mg Tablets are a key treatment in the management of hormone receptor-positive breast cancer. Available in both brand name (Arimidex®) and generic formulations, Anastrozole is used in adjuvant and metastatic settings for postmenopausal women. It works as a non-steroidal aromatase inhibitor, reducing estrogen production to slow or stop the growth of estrogen-dependent breast cancers. Anastrozole is widely available in both the U.S. and EU and is a core component of oncology B2B offerings in breast cancer therapies. With 1 mg tablets as the standard strength, it is a critical medication in global oncology markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing